ABSTRACT.
INFECTIOUS DISEASES
Financial support: This work was supported by the Bill & Melinda Gates Foundation (OPP1179069 and INV-008606).Authors’ addresses: Stephanie A. Brennhofer, Jixian Zhang, Suporn Pholwat, Suzanne Stroup, James A. Platts-Mills, and Eric R. Houpt, Division of Infectious Diseases & International Health, University of Virginia, Charlottesville, VA, E-mails: In the MORDOR I trial, children under 5 years of age were randomized to receive biannual (every 6 months) azithromycin for 2 years in Niger, Malawi, and Tanzania. In 30 Nigerien communities, children aged 7–11 years, who were not enrolled in the MORDOR I trial to receive biannual azithromycin, were assessed for carriage of seven respiratory pathogens. We aimed to see whether there were effects on the carriage of these seven respiratory pathogens among 3,187 children aged 7–11 years living in the 30 communities via nasopharyngeal swabs collected at baseline (
